Deutsch English Français

Contact

EP0863917

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP0863917

EP0863917 - TARGETED CYTOTOXIC ANTHRACYCLINE ANALOGS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 06.08.2004 Database last updated on 06.07.2024
Most recent event Tooltip	06.08.2004	No opposition filed within time limit	published on 22.09.2004 [2004/39]
Applicant(s)	For all designated states The Administrators of the Tulane Educational Fund 1430 Tulane Avenue, SL 13 New Orleans, LA 70112 / US
	[2003/12]
Former [2001/49]	For all designated states Zentaris AG Weissmüllerstrasse 45 60314 Frankfurt/Main / DE
Former [1998/38]	For all designated states ASTA Medica Aktiengesellschaft An der Pikardie 10 D-01277 Dresden / DE
Inventor(s)	01 / SCHALLY, Andrew V., Tulane University Med. Ctr School of Medicine, 1430 Tulane Avenue New Orleans, LA 70112-2699 / US
	02 / NAGY, Attila A., Tulane University Med. Ctr School of Medicine, 1430 Tulane Avenue New Orleans, LA 70112-2699 / US
	03 / CAI, Ren-Zhi, Tulane University Med. Ctr School of Medicine, 1430 Tulane Avenue New Orleans, LA 70112-2699 / US
	[1998/38]
Representative(s)	Nauwald, Gunter Zentaris AG Patente/Marken Meissner Strasse 35 D-01445 Radebeul / DE
	[N/P]
Former [2003/12]	Nauwald, Gunter Zentaris AG Patente/Marken Meissner Strasse 35 D-01445 Radebeul / DE
Former [2001/37]	(deleted)
Former [1998/38]	Sander, Uwe c/o ASTA MEDICA AKTIENGESELLSCHAFT, Meissner Strasse 35 01435 Radebeul / DE
Application number, filing date	96938216.7	14.11.1996
	[1998/38]
	WO1996EP05029
Priority number, date	US19950562652	27.11.1995 Original published format: US 562652
	[1998/38]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9719954
	Date:	05.06.1997
	Language:	EN
	[1997/24]
	Type:	A1 Application with search report
	No.:	EP0863917
	Date:	16.09.1998
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.06.1997 takes the place of the publication of the European patent application.
	[1998/38]
	Type:	B1 Patent specification
	No.:	EP0863917
	Date:	01.10.2003
	Language:	EN
	[2003/40]
Search report(s)	International search report - published on:	EP	05.06.1997
Classification	IPC:	C07K7/23, A61K47/48	[1998/38]
	CPC data not yet available
Designated contracting states	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1998/38]
Title	German:	ZIELGERICHTETE, ZYTOTOXISCHE ANTHRACYCLIN-ANALOGE	[1998/38]
	English:	TARGETED CYTOTOXIC ANTHRACYCLINE ANALOGS	[1998/38]
	French:	ANALOGUES CYTOTOXIQUES CIBLES D'ANTHRACYCLINE	[1998/38]
Entry into regional phase	13.05.1998	National basic fee paid
	13.05.1998	Designation fee(s) paid
	13.05.1998	Examination fee paid
Examination procedure	31.05.1997	Request for preliminary examination filed International Preliminary Examining Authority: EP
	13.05.1998	Examination requested [1998/38]
	13.05.2002	Despatch of a communication from the examining division (Time limit: M08)
	13.01.2003	Reply to a communication from the examining division
	19.03.2003	Communication of intention to grant the patent
	18.06.2003	Fee for grant paid
	18.06.2003	Fee for publishing/printing paid
Divisional application(s)	EP03010988.8 / EP1384710
Opposition(s)	02.07.2004	No opposition filed within time limit [2004/39]
Fees paid	Renewal fee
	11.11.1998	Renewal fee patent year 03
	10.11.1999	Renewal fee patent year 04
	19.01.2001	Renewal fee patent year 05
	27.10.2001	Renewal fee patent year 06
	31.10.2002	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	30.11.2000	05 M06 Fee paid on 19.01.2001
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[DX]US4299822 (ISRAEL MERVYN, et al) [DX] 1,32,33 * example -; claim - *;
		[X]GB2124224 (STANFORD RES INST INT) [X] 1,32,33 * example -; claim - *;
		[DX]EP0434960 (ERBA CARLO SPA [IT]) [DX] 1,32,33 * example -; claim - *;
		[DA]EP0450461 (SCHALLY ANDREW VICTOR [US], et al) [DA] 1,2,32-36 * the whole document *;
		[A]EP0624377 (BRISTOL MYERS SQUIBB CO [US]) [A] 1,32,33 * reaction schemes 12, 15, 16, 18;; examples 8,9,14,15,23 * * examples 24,28,48,49 * * examples 61,70,71; claim - *;
		[DX] - A. CHERIF AND D. FARQUHAR, "N-(5,5-Diacetoxypent-1-yl)doxorubicin: A New Intensely Potent Doxorubicin Analogue", JOURNAL OF MEDICINAL CHEMISTRY, WASHINGTON US, (19920821), vol. 35, no. 17, pages 3208 - 3214, XP002029565 [DX] 1,32,33 * see chart I, Scheme I, scheme III; page 3210, column R, paragraph 4 - page 3212, column L, paragraph 3 * DOI: http://dx.doi.org/10.1021/jm00095a017
		[DX] - MUELLER B M ET AL, "ANTIBODY CONJUGATES WITH MORPHOLINODOXORUBICIN AND ACID-CLEAVABLE LINKERS", BIOCONJUGATE CHEMISTRY, (19900901), vol. 1, no. 5, pages 325 - 330, XP000174625 [DX] 1,32,33 * see scheme I and scheme II; page 327, column L, paragraph 1 - page 329, column L, paragraph 2 * DOI: http://dx.doi.org/10.1021/bc00005a005
		[DX] - F. ZUNINO ET AL., "Comparison of Antitumor Effects of Aunorubicin Covalently Linked to Poly-L-Amino Acid Carriers", EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY, (198403), vol. 20, no. 3, pages 421 - 425, XP000670366 [DX] 1,32,33 * page 421, column R, paragraph 3 - page 422, column L, paragraph 1 * * page 424, column L, paragraph 2 - page 425, column L, paragraph 1 * DOI: http://dx.doi.org/10.1016/0277-5379(84)90091-9
		[DA] - A.V. SCHALLY, "Hypothalamic Hormones: from neuroendocrinology to cancer therapy", ANTI-CANCER DRUGS, (199404), vol. 5, no. 2, pages 115 - 130, XP000670356 [DA] 1,2,32,33 * page 120, column R, paragraph 2 - page 121, column L, paragraph 1 *
		[DA] - A. TROUET ET AL., "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate. In vitro and in vivo studies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, WASHINGTON US, (198201), vol. 79, pages 626 - 629, XP002029566 [DA] 1 * figure 1 * DOI: http://dx.doi.org/10.1073/pnas.79.2.626

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p